IO Biotech has a unique and novel technology platform, T-win, for developing immune modulating anti-cancer therapies
The discovery of naturally occurring, proinflammatory T-cells specific for immune inhibitory molecules (e.g., IDO and PD-L1) – termed ‘anti-regulatory T-cells’ - laid the basis for the IO Biotech approach. We aim to target and activate these self-reactive T-cells that can specifically remove the unwanted cells in the tumor microenvironment.
IO Biotech’s immune modulating anti-cancer therapies have a multifaceted mode of actions: they activate the patients’ own cytotoxic T-cells towards immune suppressive cells or cancer cells presenting the target peptide, hence the anti-cancer therapies act in two ways:
- Direct anti-cancer effect by killing of target expressing tumor cells
- Elimination of immune-suppressive cells, thereby augmenting the effector responses of surrounding T-cells in treated cancer patients
In addition, immune modulating anti-cancer therapies have the potential to induce long-term immunity.
Illustration of T-win technology platform
Publications by founders